Verona Pharma price target raised to $57 from $44 at Truist

Jan 8, 2025 · Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the company’s positive Q4 revenue pre-announcement reflecting ...

$57
OFF

Verona Pharma Price Target Raised To $57 From $44 At Truist

2 weeks from now

businessinsider.com

$57.00
OFF

Verona Pharma (NASDAQ:VRNA) Earns "Buy" Rating From Truist

2 weeks from now

6 days ago · Truist Financial reissued a "buy" rating and issued a $57.00 price objective (up from $44.00) on shares of Verona Pharma in a research note on Wednesday. ... HC Wainwright …

marketbeat.com

$57.00
OFF

Verona Pharma (NASDAQ:VRNA) Upgraded To Strong-Buy At Roth …

2 weeks from now

3 days ago · Truist Financial reiterated a "buy" rating and set a $57.00 price target (up previously from $44.00) on shares of Verona Pharma in a report on Wednesday. Canaccord Genuity …

marketbeat.com

$57.00
OFF

Roth Mkm Begins Coverage On Verona Pharma (NASDAQ:VRNA)

2 weeks from now

1 day ago · Finally, Truist Financial reissued a “buy” rating and set a $57.00 price target (up previously from $44.00) on shares of Verona Pharma in a report on Wednesday, January 8th.

etfdailynews.com

$57.00
OFF

Verona Pharma (NASDAQ:VRNA) Receives “Buy” Rating From …

2 weeks from now

4 days ago · Truist Financial currently has a $57.00 target price on the stock, up from their prior target price of $44.00. ... Wells Fargo & Company raised their target price on Verona Pharma …

etfdailynews.com

$57
OFF

Truist Financial Remains A Buy On Verona Pharma (VRNA)

2 weeks from now

Jan 6, 2025 · Verona Pharma price target raised to $57 from $44 at Truist. ... Verona Pharma price target raised to $77 from $51 at BTIG. TipRanks 7h. Wells Fargo Sticks to Their Buy …

businessinsider.com

$37.00
OFF

Verona Pharma Plc (NASDAQ:VRNA) Given Consensus

2 weeks from now

4 days ago · Canaccord Genuity Group raised their price target on shares of Verona Pharma from $37.00 to $44.00 and gave the stock a "buy" rating in a research note on Tuesday, November …

marketbeat.com

$42
OFF

Truist Financial Releases A Buy Rating On Verona Pharma (VRNA)

2 weeks from now

Dec 23, 2024 · Verona Pharma price target raised to $42 from $36 at H.C. Wainwright; ... Verona Pharma price target raised to $57 from $44 at Truist. TipRanks 5h.

businessinsider.com

$57.00
OFF

Brokerages Set Verona Pharma Plc (NASDAQ:VRNA) Target Price …

2 weeks from now

1 day ago · Finally, Truist Financial restated a “buy” rating and issued a $57.00 target price (up previously from $44.00) on shares of Verona Pharma in a report on Wednesday, January 8th.

etfdailynews.com

50%
OFF

Verona Pharma Plc Buy Truist Financial Co. - Sharewise

2 weeks from now

6 days ago · Verona Pharma plc buy Truist Financial Co. Verona Pharma plc. Start price €0.51. 08.01.25 / 50%. Target price €55.32. ... Verona Pharma plc (NASDAQ: VRNA) had its "buy" …

sharewise.com

$57
OFF

Verona Pharma’s Ohtuvayre: Unique COPD Solution ... - Markets …

2 weeks from now

5 days ago · Verona Pharma price target raised to $57 from $44 at Truist; Verona Pharma price target raised to $74 from $64 at Wells Fargo; Verona Pharma price target raised to $77 from …

businessinsider.com

$57
OFF

Verona Pharma (VRNA) PT Raised To $57 At Truist Securities As …

2 weeks from now

6 days ago · Truist Securities analyst Joon Lee raised the price target on Verona Pharma (NASDAQ: VRNA) to $57.00 (from $44.00) while maintaining a Buy rating.The analyst said: …

streetinsider.com

65%
OFF

Wall Street Analysts See A 30.65% Upside In Verona Pharma …

2 weeks from now

12 hours ago · The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after …

yahoo.com

$64.00
OFF

Verona Pharma (NASDAQ:VRNA) Upgraded By Roth Capital To …

2 weeks from now

2 days ago · Wells Fargo & Company raised their target price on shares of Verona Pharma from $64.00 to $74.00 and gave the company an “overweight” rating in a report on Wednesday.

etfdailynews.com

$57
OFF

Verona Pharma Initiated With A Buy At Roth MKM - Markets Insider

2 weeks from now

5 days ago · Verona Pharma price target raised to $57 from $44 at Truist; Verona Pharma price target raised to $74 from $64 at Wells Fargo; Verona Pharma price target raised to $77 from …

businessinsider.com

$44
OFF

Truist Securities Reiterates Buy On Verona Pharma, Raises Price …

2 weeks from now

Jan 8, 2025 · Truist Securities analyst Joon Lee reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and raises the price target from $44 to $57.

sahmcapital.com

5%
OFF

Verona Pharma (NASDAQ:VRNA) Stock Price Up 4.5% - MarketBeat

2 weeks from now

2 days ago · Roth Capital raised Verona Pharma to a "strong-buy" rating in a research report on Friday. Finally, Truist Financial reissued a "buy" rating and issued a $57.00 price objective (up …

marketbeat.com

$74
OFF

Verona Pharma Price Target Raised To $74 From $64 At Wells Fargo

2 weeks from now

6 days ago · Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $74 from $64 and keeps an Overweight rating on the shares. The firm notes …

nasdaq.com

$74
OFF

Verona Pharma Price Target Raised To $74 From $64 At Wells Fargo

2 weeks from now

Jan 8, 2025 · Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma to $74 from $64 and keeps an Overweight rating on the shares.The firm notes preliminary Q4 …

businessinsider.com

FAQs about Verona Pharma price target raised to $57 from $44 at Truist Coupon?

Is Verona Pharma a good stock to buy?

The firm issued a buy rating and a $68.00 price objective on the stock. Several other equities analysts have also commented on the stock. Wells Fargo & Company raised their target price on shares of Verona Pharma from $64.00 to $74.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. ...

Should you buy Verona Pharma (vRNA)?

Verona Pharma (NASDAQ:VRNA – Get Free Report) was upgraded by investment analysts at Roth Capital to a “strong-buy” rating in a report released on Friday, Zacks.com reports. A number of other equities research analysts also recently commented on VRNA. ...

Who owns Verona Pharma?

Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock worth $75,000 after purchasing an additional 529 shares during the period. Diversify Advisory Services LLC bought a new position in Verona Pharma during the third quarter worth $169,000. ...

Does Mirae own Verona Pharma?

Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Verona Pharma by 25.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock worth $75,000 after purchasing an additional 529 shares during the period. ...

Does Frazier life sciences management own Verona Pharma?

Frazier Life Sciences Management L.P. boosted its holdings in shares of Verona Pharma by 2.1% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 3,383,950 shares of the company’s stock valued at $97,356,000 after acquiring an additional 69,601 shares during the last quarter. ...

Does a consensus price target indicate a potential upside in vRNA?

However, an impressive consensus price target is not the only factor that indicates a potential upside in VRNA. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. ...